Background 95% confidence interval CI, 0.715–0.910; p <0.001) and OS (HR, 0.850; 95% CI, 0.733–0.985; p =0.031). The objective response rate was significantly higher in the Target group ( p =0.023), while treatment-related adverse event rates were comparable across the BBI groups, with no significant differences in proteinuria, hypertension, or other toxicities. Conclusions: BSA-adjusted bevacizumab dosing was associated with improved efficacy without increased toxicity in patients with unresectable HCC treated with Atezo/Bev.
Aoe et al. (Wed,) studied this question.